Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.

Few new compounds are available for relapsed osteosarcoma. We retrospectively evaluated the activity of gemcitabine (G) plus docetaxel (D) in patients with relapsed high-grade osteosarcoma and high-grade spindle cell sarcoma of bone (HGS).

Patients receiving G 900 mg/m(2) d 1, 8; D 75 mg/m(2) d 8, every 21 days were eligible. Primary end-point: progression-free survival (PFS) at 4 months; secondary end-point: overall survival (OS) and response rate.

Fifty-one patients were included, with a median age of 17 years (8-71), 26 (51%) were pediatric patients. GD line of treatment: 2nd in 14 patients, ≥3rd in 37. 25 (49%) patients had metastases limited to lungs, 26 (51%) multiple sites.

40 (78%) osteosarcoma, 11 (22%) HGS. Eight (16%) patients achieved surgical complete response (sCR2) after GD. Four-month PFS rate was 46%, and significantly better for patients with ECOG 0 (ECOG 0: 54% vs ECOG 1: 43% vs ECOG 2: 0%; p = 0.003), for patients undergoing metastasectomy after GD (sCR2 75% vs no-sCR2 40 %, p = 0.02) and for osteosarcoma (osteosarcoma 56% vs HGS 18%; p = 0.05), with no differences according to age, line of treatment, and pattern of metastases. Forty-six cases had RECIST measurable disease: 6 (13%) patients had a partial response (PR), 20 (43%) had stable disease (SD) and 20 (43%) had progressive disease (PD). The 1-year OS was 30%: 67% for PR, 54% for SD and 20% for PD (p = 0.005).

GD is an active treatment for relapsed high-grade osteosarcoma, especially for ECOG 0 patients, and should be included in the therapeutic armamentarium of metastatic osteosarcoma.

BMC cancer. 2016 Jan 20*** epublish ***

E Palmerini, R L Jones, E Marchesi, A Paioli, M Cesari, A Longhi, C Meazza, L Coccoli, F Fagioli, S Asaftei, G Grignani, A Tamburini, S M Pollack, P Picci, S Ferrari

PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy. This email address is being protected from spambots. You need JavaScript enabled to view it.., University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, USA., PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy., Oncoematologia Pediatrica INT, Milan, Italy., UO Oncoematologia Pediatrica Pisa, Pisa, Italy., Oncoematologia Pediatrica Torino, Torino, Italy., IRCCS Candiolo, Torino, Italy., Oncoematologia Azienda Ospedaliera Universitaria Meyer Pediatrica, Firenze, Italy., Laboratory Research, Istituto Ortopedico Rizzoli, Bologna, Italy.